Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
Open Access
- 31 March 2020
- Vol. 12 (4), 842
- https://doi.org/10.3390/cancers12040842
Abstract
Chimeric antigen receptors (CAR) are fusion proteins engineered from antigen recognition, signaling, and costimulatory domains that can be used to reprogram T cells to specifically target tumor cells expressing specific antigens. Current CAR-T cell technology utilizes the patient’s own T cells to stably express CARs and has achieved exciting clinical success in the past few years. However, current CAR-T cell therapy still faces several challenges, including suboptimal persistence and potency, impaired trafficking to solid tumors, local immunosuppression within the tumor microenvironment and intrinsic toxicity associated with CAR-T cells. This review focuses on recent strategies to improve the clinical efficacy of CAR-T cell therapy and other exciting CAR approaches currently under investigation, including CAR natural killer (NK) and NKT cell therapies.This publication has 112 references indexed in Scilit:
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancerBlood, 2012
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patientsBlood, 2011
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody ReceptorClinical Cancer Research, 2011
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patientsJCI Insight, 2011
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBlood, 2008
- The Biology of NKT CellsAnnual Review of Immunology, 2007
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005